Covid-19 roundup: Ger­many pours near­ly $450M in­to BioN­Tech; As­traZeneca still has­n't re­sumed its vac­cine tri­al in the US

Pfiz­er CEO Al­bert Bourla has made a point since the pan­dem­ic’s ear­ly days of re­ject­ing US as­sis­tance for their Covid-19 vac­cine, sep­a­rat­ing them from the rest of the big play­ers and cast­ing the old phar­ma gi­ant as a dy­nam­ic com­pa­ny that could move bet­ter and faster alone.

The sto­ry, though, for their Ger­man biotech part­ner BioN­Tech — the com­pa­ny whose mR­NA tech­nol­o­gy is ac­tu­al­ly be­hind their vac­cine — is a lit­tle dif­fer­ent. In June, the Eu­ro­pean In­vest­ment Bank gave BioN­Tech €100 mil­lion debt fi­nanc­ing to sup­port man­u­fac­tur­ing and de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.